Objective To explore the action mechanism of Sanqi（ Radix Notoginseng） in treating atherosclerosis. Methods Based on Traditional Chinese Medicine Systematic Pharmacology（ TCMSP） database

oral bioavailability（ OB） ≥30%

drug likeness（ DL） ≥ 0. 18

cell permeability（ Caco-2） ≥-0. 4 were taken as screening condition. Combined with the literature

the effective active ingredients of Radix Notoginseng was obtained. The target of active ingredients and related diseases were extracted through PharmMapper database. All targets of atherosclerosis were collected in OMIM

TTD

Drugbank and other databases. An active "ingredients-disease-target"network map was constructed

and was verified with the selected targets. The DAVID database was used for GO analysis and KEGG pathway enrichment analysis of the key targets. Results Totally 11 active components such as ginsenoside rh2

quercetin and β-sitosterol were screened by network pharmacology to act on 92 targets and 269 related diseases.Nine targets for direct treatment of atherosclerosis were leukotriene A4 hydrolase（ LTA4 H）

arachidonic acid 5 lipoxygenase（ ALOX5）

matrix metalloproteinase 3（ MMP3）

urokinase-type fibrinolysis Proenzyme activator（ PLAU）

tumor necrosis factor（ TNF）

interleukin 1β（ IL1 B）

human E-selectin（ SELE）

myeloperoxidase（ MPO）

retinol X receptor alpha（ RXRA）. GO analysis showed that biological processes were closely related to inflammation

including leukotriene metabolism and synthesis

and regulation of I-κB kinase/NF-κB signaling. KEGG analysis revealed multiple functions and signaling pathways associated with atherosclerosis. Conclusion The active constituents of Radix Notoginseng can directly regulate atherosclerosis-related targets

indirectly regulate key inflammatory factors

and then regulate inflammatory factor-related NF-κB signaling pathways and TNF signaling pathways to play a role in the treatment of atherosclerosis.